دورية أكاديمية
Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.
| العنوان: | Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. |
|---|---|
| المؤلفون: | Nelsen LM; Patient Centered Outcomes, Value Evidence and Outcomes, GSK, Collegeville, PA, USA., Cockle SM; Value Evidence and Outcomes, GSK House, Brentford, UK., Gunsoy NB; Clinical Statistics, GSK, Stockley Park, UK., Jones P; Respiratory Medical, GSK House, Brentford, UK., Albers FC; Respiratory Medical Franchise, GSK SK, Research Triangle Park, NC, USA., Bradford ES; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA., Mullerova H; Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, UK. |
| المصدر: | The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2020 Sep; Vol. 57 (9), pp. 1006-1016. Date of Electronic Publication: 2019 Jun 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4303 (Electronic) Linking ISSN: 02770903 NLM ISO Abbreviation: J Asthma Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: [Ossining, N.Y. : Asthma Publications Society, c1981- |
| مواضيع طبية MeSH: | Health Status* , Severity of Illness Index* , Symptom Flare Up*, Asthma/*diagnosis , Eosinophilia/*diagnosis, Adolescent ; Adult ; Aged ; Anti-Asthmatic Agents/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Asthma/complications ; Asthma/drug therapy ; Eosinophilia/complications ; Eosinophilia/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Observational Studies as Topic ; Randomized Controlled Trials as Topic ; Surveys and Questionnaires/statistics & numerical data ; Young Adult |
| مستخلص: | Objective: To assess the effect of asthma exacerbations and mepolizumab treatment on health status of patients with severe asthma using the St George's Respiratory Questionnaire (SGRQ). Methods: Post hoc analyses were conducted using data from two randomized controlled trials in patients ≥12 years old with severe eosinophilic asthma randomized to receive placebo or mepolizumab 75 mg intravenously (32-week MENSA study) or 100 mg subcutaneously (MENSA/24-week MUSCA studies), and an observational single-visit study in patients with severe asthma (IDEAL). Linear regression models assessed the impact of historical exacerbations on baseline SGRQ total and domain scores (using data from each of the three studies), and within-study severe exacerbations and mepolizumab treatment on end-of-study SGRQ scores (using data from MENSA/MUSCA). Results: Overall, 1755 patients were included (MENSA, N = 540; MUSCA, N = 551; IDEAL, N = 664). In all studies, higher numbers of historical exacerbations were associated with worse baseline SGRQ total scores. Each additional historical exacerbation (beyond the second [MENSA/MUSCA]) or first [IDEAL] was associated with worsening mean total SGRQ scores of +1.5, +1.1 at baseline and +2.3 within the year prior to study enrollment. During MENSA and MUSCA, each within-study severe exacerbation was associated with a worsening in total SGRQ score of +2.4 and +3.4 points at study end. Independent of exacerbation reduction, mepolizumab accounted for an improvement in total SGRQ score of -5.3 points (MENSA) and -6.2 points (MUSCA). Conclusions: These findings support an association between a higher number of exacerbations and worse health status in patients with severe (eosinophilic) asthma. |
| فهرسة مساهمة: | Keywords: biologics; health status; mepolizumab; quality of life; severe eosinophilic asthma |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02293265; NCT01691521; NCT02281318 |
| المشرفين على المادة: | 0 (Anti-Asthmatic Agents) 0 (Antibodies, Monoclonal, Humanized) 90Z2UF0E52 (mepolizumab) |
| تواريخ الأحداث: | Date Created: 20190629 Date Completed: 20210303 Latest Revision: 20210303 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1080/02770903.2019.1630640 |
| PMID: | 31251094 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1532-4303 |
|---|---|
| DOI: | 10.1080/02770903.2019.1630640 |